Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Receivables: 2021-2024

Historic Receivables for Mirum Pharmaceuticals (MIRM) over the last 4 years, with Dec 2024 value amounting to $78.3 million.

  • Mirum Pharmaceuticals' Receivables rose 56.33% to $107.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $388.1 million, marking a year-over-year increase of 54.05%. This contributed to the annual value of $78.3 million for FY2024, which is 15.18% up from last year.
  • Mirum Pharmaceuticals' Receivables amounted to $78.3 million in FY2024, which was up 15.18% from $68.0 million recorded in FY2023.
  • Over the past 5 years, Mirum Pharmaceuticals' Receivables peaked at $78.3 million during FY2024, and registered a low of $3.3 million during FY2021.
  • For the 3-year period, Mirum Pharmaceuticals' Receivables averaged around $56.7 million, with its median value being $68.0 million (2023).
  • Data for Mirum Pharmaceuticals' Receivables shows a peak YoY spiked of 634.44% (in 2022) over the last 5 years.
  • Mirum Pharmaceuticals' Receivables (Yearly) stood at $3.3 million in 2021, then skyrocketed by 634.44% to $24.0 million in 2022, then soared by 183.27% to $68.0 million in 2023, then rose by 15.18% to $78.3 million in 2024.